Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate Theory for Treatment of Alzheimer’s Disease
2022-08-18
Publication in NatureMolecular Psychiatry Supports Genuv’s Alternate Theory for Treatment of Alzheimer’s Disease
Article in peer-reviewed publication provides validation of Genuv’s novel neuroprotection approach to Alzheimer’s disease
SEOUL, Republic of Korea--(BUSINESS WIRE)--Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for central nervous system disorders and advanced antibody therapies for immuno-oncology, announced the publication of a manuscript in Molecular Psychiatry, a peer-reviewed scientific journal published by Springer Nature Group. The new research provides important validation for the company’s six-year effort to develop new treatments for neurodegenerative diseases including Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).
